Cargando…

Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada

OBJECTIVE: Our objective was to evaluate the cost effectiveness of the combination of nivolumab and ipilimumab, referred to as “Regimen”, as a first-line treatment for patients with advanced melanoma from the perspective of Canada’s public healthcare system. METHODS: We developed a partitioned-survi...

Descripción completa

Detalles Bibliográficos
Autores principales: Quon, Peter L., Xiao, Ying, Sorensen, Sonja, Monfared, Amir Abbas Tahami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710483/
https://www.ncbi.nlm.nih.gov/pubmed/30617952
http://dx.doi.org/10.1007/s41669-018-0112-1